中國聯通(00762.HK):廣西聯通與合作方簽署綜合改革合作協議
格隆匯5月19日丨中國聯通(00762.HK)公佈,2020年5月19日,廣西聯通與公開招募的聯合體合作方北京市電信工程局和華控投資,以及合作方中電興發股份公司分別簽署了《中國聯合網絡通信有限公司廣西壯族自治區分公司綜合改革合作協議》。
根據上述兩個合作協議,(1)廣西聯通與聯合體合作方北京市電信工程局和華控投資在廣西柳州等3個市分公司開展接入網資產投資、創新業務投資、委託運營等方面合作,首次合作期截止至2030年12月31日;(2)廣西聯通與合作方中電興發股份公司在廣西貴港等4個市分公司開展接入網資産投資、創新業務投資、委託運營等方面合作,首次合作期截止至2030年12月31日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.